| Telaprevir for retreatment of HCV infection S Zeuzem, P Andreone, S Pol, E Lawitz, M Diago, S Roberts, R Focaccia, ... New England Journal of Medicine 364 (25), 2417-2428, 2011 | 2118 | 2011 |
| Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study S Blach, S Zeuzem, M Manns, I Altraif, AS Duberg, DH Muljono, I Waked, ... The lancet Gastroenterology & hepatology 2 (3), 161-176, 2017 | 2075 | 2017 |
| Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study D Razavi-Shearer, I Gamkrelidze, MH Nguyen, DS Chen, P Van Damme, ... The lancet Gastroenterology & hepatology 3 (6), 383-403, 2018 | 1494 | 2018 |
| Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial ZM Younossi, V Ratziu, R Loomba, M Rinella, QM Anstee, Z Goodman, ... The Lancet 394 (10215), 2184-2196, 2019 | 1051 | 2019 |
| Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection GR Foster, N Afdhal, SK Roberts, N Bräu, EJ Gane, S Pianko, E Lawitz, ... New England Journal of Medicine 373 (27), 2608-2617, 2015 | 1044 | 2015 |
| COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study VJ Hall, S Foulkes, A Saei, N Andrews, B Oguti, A Charlett, E Wellington, ... The Lancet 397 (10286), 1725-1735, 2021 | 759 | 2021 |
| SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN) VJ Hall, S Foulkes, A Charlett, A Atti, EJM Monk, R Simmons, E Wellington, ... The Lancet 397 (10283), 1459-1469, 2021 | 672 | 2021 |
| The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm H Razavi, I Waked, C Sarrazin, RP Myers, R Idilman, F Calinas, W Vogel, ... Journal of viral hepatitis 21, 34-59, 2014 | 558 | 2014 |
| Investigation of the safety of irreversible electroporation in humans KR Thomson, W Cheung, SJ Ellis, D Federman, H Kavnoudias, ... Journal of Vascular and Interventional Radiology 22 (5), 611-621, 2011 | 552 | 2011 |
| Glecaprevir–pibrentasvir for 8 or 12 weeks in HCV genotype 1 or 3 infection S Zeuzem, GR Foster, S Wang, A Asatryan, E Gane, JJ Feld, T Asselah, ... New England Journal of Medicine 378 (4), 354-369, 2018 | 472 | 2018 |
| Historical epidemiology of hepatitis C virus (HCV) in selected countries P Bruggmann, T Berg, ALH Øvrehus, C Moreno, CE Brandão Mello, ... Journal of viral hepatitis 21, 5-33, 2014 | 412 | 2014 |
| Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind … EJ Gane, SK Roberts, CAM Stedman, PW Angus, B Ritchie, R Elston, ... The Lancet 376 (9751), 1467-1475, 2010 | 402 | 2010 |
| Prognosis of histological cirrhosis in type 1 autoimmune hepatitis SK Roberts, TM Therneau, AJ Czaja Gastroenterology 110 (3), 848-857, 1996 | 363 | 1996 |
| D-livering the message: the importance of vitamin D status in chronic liver disease MT Kitson, SK Roberts Journal of hepatology 57 (4), 897-909, 2012 | 311 | 2012 |
| Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study S Blach, NA Terrault, F Tacke, I Gamkrelidze, A Craxi, J Tanaka, I Waked, ... The Lancet Gastroenterology & Hepatology 7 (5), 396-415, 2022 | 308 | 2022 |
| Morphological, molecular, and functional heterogeneity of cholangiocytes from normal rat liver G Alpini, S Roberts, SM Kuntz, Y Ueno, S Gubba, PV Podila, G LeSage, ... Gastroenterology 110 (5), 1636-1643, 1996 | 296 | 1996 |
| Efficacy of 8 weeks of sofosbuvir, velpatasvir, and voxilaprevir in patients with chronic HCV infection: 2 phase 3 randomized trials IM Jacobson, E Lawitz, EJ Gane, BE Willems, PJ Ruane, RG Nahass, ... Gastroenterology 153 (1), 113-122, 2017 | 294 | 2017 |
| Strategies to manage hepatitis C virus (HCV) disease burden H Wedemeyer, AS Duberg, M Buti, WM Rosenberg, S Frankova, G Esmat, ... Journal of viral hepatitis 21, 60-89, 2014 | 272 | 2014 |
| Faldaprevir and deleobuvir for HCV genotype 1 infection S Zeuzem, V Soriano, T Asselah, JP Bronowicki, AW Lohse, B Müllhaupt, ... New England Journal of Medicine 369 (7), 630-639, 2013 | 255 | 2013 |
| The oral toll-like receptor-7 agonist GS-9620 in patients with chronic hepatitis B virus infection EJ Gane, YS Lim, SC Gordon, K Visvanathan, E Sicard, RN Fedorak, ... Journal of hepatology 63 (2), 320-328, 2015 | 238 | 2015 |
